TSHA · NASDAQ
Taysha Gene Therapies (TSHA) Stock Price & Fundamentals
Taysha Gene Therapies (TSHA) closed at $511.85 on Oct 9, 2026, down 1.22% from the previous close of $518.18.
Share price, past year
1Y +0.35%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $511.85 |
| Sep 30, 2026 | $517.38 |
| Aug 31, 2026 | $517.06 |
| Jul 31, 2026 | $543.97 |
| Jun 30, 2026 | $540.07 |
| May 29, 2026 | $486.40 |
| Apr 30, 2026 | $472.46 |
| Mar 31, 2026 | $498.92 |
| Feb 27, 2026 | $491.48 |
| Jan 30, 2026 | $500.96 |
| Dec 31, 2025 | $484.80 |
| Nov 28, 2025 | $494.82 |
| Oct 31, 2025 | $481.46 |
Key statistics
- Market cap
- $166.51B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.42
- Revenue (TTM)
- $5.49M
- Net income (TTM)
- −$149.63M
- Shares outstanding
- 325.3M
- Dividend yield
- —
- 52-week range
- $469.31 – $564.74
Taysha Gene Therapies's market cap is $166.51B, based on a share price of $511.85 and 325.3M shares outstanding as of Jun 30, 2026.
Financials
Taysha Gene Therapies reported revenue of $9.77M for fiscal 2025, up 17.28% from fiscal 2024.
Taysha Gene Therapies reported a net loss of $109.00M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $9.77M | +17.3% | −$109.00M | −1,115.3% | −$0.34 | −$93.83M |
| FY2024ended Dec 31, 2024 | $8.33M | −46.1% | −$89.30M | −1,071.6% | −$0.36 | −$81.60M |
| FY2023ended Dec 31, 2023 | $15.45M | +517.6% | −$111.57M | −722.1% | −$0.96 | −$76.89M |
| FY2022ended Dec 31, 2022 | $2.50M | — | −$166.01M | −6,635.3% | −$3.78 | −$109.01M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$46.64M | −$0.13 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$42.41M | −$0.12 |
| Q4 FY2025ended Dec 31, 2025 | $5.49M | −$27.85M | −$0.08 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$32.73M | −$0.09 |
| Q2 FY2025ended Jun 30, 2025 | $1.99M | −$26.88M | −$0.09 |
| Q1 FY2025ended Mar 31, 2025 | $2.30M | −$21.53M | −$0.08 |
| Q4 FY2024ended Dec 31, 2024 | $2.02M | −$18.79M | −$0.07 |
| Q3 FY2024ended Sep 30, 2024 | $1.79M | −$25.52M | −$0.10 |
Company profile
- Name
- Taysha Gene Therapies, Inc.
- Ticker
- TSHA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 3000 Pegasus Park Drive, Suite 1430, Dallas, TX 75247
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001806310
Recent SEC filings
- Aug 11, 2026
- Aug 11, 2026
- Jun 25, 2026
- Jun 22, 2026
- Jun 2, 2026
- May 6, 2026
- May 6, 2026
- Mar 19, 2026
Frequently asked questions
What is Taysha Gene Therapies's stock price?
Taysha Gene Therapies (TSHA) closed at $511.85 on Oct 9, 2026, down 1.22% from the previous close of $518.18.
What is Taysha Gene Therapies's market cap?
Taysha Gene Therapies's market cap is $166.51B, based on a share price of $511.85 and 325.3M shares outstanding as of Jun 30, 2026.
How much revenue does Taysha Gene Therapies make?
Taysha Gene Therapies reported revenue of $9.77M for fiscal 2025, up 17.28% from fiscal 2024.
Does Taysha Gene Therapies pay a dividend?
Taysha Gene Therapies's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Taysha Gene Therapies, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures